Editorial Board
Xintao Hu
National Cancer Institute
Editorial leadership for Journal of Immunization ISSN 2577-137X
Research interests
- Virology
- Immunology Mainly Including The Following Directions: 1) Infection
- Immunity For Medical Viruses Including Hiv/Aids;&Nbsp; 2) Dissection Of Immune Protection Mechanism Of Candidate Vaccines Against Siv/Hiv; 3) Immunization Strategy Optimization
- Novel Adjuvant Discovery; 4) Rational Development Of Preventive
- Therapeutic Strategy Against Retroviruses Including Siv/Hiv
Biography
- I was enrolled as Graduate Partnerships Program at NIH, USA and awarded pre-doctoral fellow by Vaccine Research Center at NIAID to conduct my Ph.D. dissertation research from 2011.
- After obtaining my Ph.D. degree in immunology from Chinese Center of Disease Control and Prevention (China CDC), Beijing, China in 2012, I continued my research work at National Cancer Institute at NIH, USA. During my Ph.D. study, my research efforts focused on dissecting the adaptive immune responses especially humoral immune responses mounted during natural HIV-1 infection to inform valuable information for rational preventive and therapeutic strategy development against AIDS/HIV.
- Now, my research efforts extended to the novel vaccine development against HIV/SIV and testing them in the non-human primate model and further identified the immune protection mechanism of candidate vaccines against SIV/HIV.
- Additionally, I am exploring the novel combined therapy strategies including gene therapy and immunization approaches to eradicate/remiss the latent reservoir for HIV/SIV.
- I serve as editor board member for the Academia Journal of Scientific Research, the Journals of Scientific & Academic Publishing, the BAOJ HIV and the ARC Journal of AIDS journals.
- As well, I am invited as the reviewer for several international peer-reviewed journals and also member of American Society for Microbiology (ASM) and the American Association for the Advancement of Science (AAAS).
Considering JI for your work?
This journal is guided by Xintao Hu (National Cancer Institute) and a peer-review board of practising researchers. Open access, author-retained copyright (CC BY), and a clear editorial process.